Pokeacell
Immunotherapy company with a proprietary technology for personalized T cell therapy of late stage cancer.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
N/A | Spinout | ||
| Total Funding | 000k | ||
| DKK | 2021 | 2022 | 2024 |
|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
PokeAcell is a clinical-stage immunotherapy company established in 2020 as a spin-out from the Technical University of Denmark (DTU). The company was co-founded by Professor Sine R. Hadrup, a recognized expert in T-cell immunology whose research forms the basis of the company's core technology. Her work focuses on training the immune system's T-cells to more effectively recognize and attack cancer cells, leading to advancements in personalized immunotherapy. PokeAcell operates in the oncology market, developing personalized T-cell therapies aimed at providing lasting responses for patients with late-stage solid tumors.
The company's core offering is centered around its licensed ImmPACT technology, which activates and expands cancer-specific T-cells from a patient's own blood. These specially trained T-cells are then administered back to the patient as a personalized treatment. This process is designed to treat aggressive cancers with limited treatment options, such as Metastatic Melanoma and Merkel Cell Carcinoma, with the potential to be adapted for other solid tumors. In March 2022, a partnership including PokeAcell was awarded a $4 million grant from Innovation Fund Denmark to clinically test the ImmPACT cell product in Merkel cell carcinoma.
PokeAcell's business model revolves around the clinical development and subsequent commercialization of its T-cell therapies. The company's products, including Poke-101 for Melanoma, are in early-phase clinical trials. The company's initial funding included a $1.48M accelerator round in March 2020. By creating a personalized cell product, PokeAcell aims to address the critical need for more effective treatments for cancer patients.
Keywords: personalized T-cell therapy, immunotherapy, oncology, solid tumors, cell therapy, cancer treatment, clinical-stage, Merkel Cell Carcinoma, Metastatic Melanoma, Technical University of Denmark spin-out, ImmPACT technology, clinical trials, cancer research, biopharmaceutical, life sciences, T-cell activation, adoptive cell transfer, Sine R. Hadrup, Copenhagen, Denmark